A groundbreaking research project has revealed that the public is urging the government to prioritise primary and community care over hospitals.
The study also found a strong public willingness to pay higher taxes to enhance NHS services.
The Health Foundation and Ipsos UK conducted the research, combining nationwide polling with in-depth public deliberative workshops.
These workshops, held in King's Lynn, Leeds, and London, constitute one of the most comprehensive public consultations about the future of the NHS in England.
The study published on 16 May underscores the public's desire for a redistribution of NHS resources. If the NHS budget remains unchanged, 60 per cent of those
polled believe the government should focus on improving access to community-based services like general practice and dentistry.
The government has allocated an additional 350 medical school places in England, making a significant step in delivering the NHS Long Term Workforce Plan.
Supported by more than £2.4 billion in government funding, the plan outlines the strategy for recruiting and retaining hundreds of thousands more staff over the
next 15 years to deliver the future workforce the NHS requires.
One of the key commitments of the NHS Long Term Workforce Plan is to double the number of medical school places in England to 15,000 by 2031.
As part of the ongoing efforts to fulfill this pledge, the Office for Students (OfS) has designated 350 places for medical schools nationwide for the academic year
2025 to 2026, targeting under-doctored areas.
The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of
viruses that includes Nipah virus.
Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of
outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness.
Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which
mimics the infection in humans.
Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect
health from this "current and future global health threat."
"The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic
by accelerating the development of diagnostics, therapeutics and vaccines," he added.
In recent years, the healthcare sector has seen a significant transformation driven by the rapid advancement of technology. From improved patient care to
streamlined administrative processes, technology has become an indispensable part of modern healthcare. As medical facilities worldwide embrace these innovations,
it's essential to understand why the sector leans so heavily on advanced technological solutions. Below are seven key reasons illustrating the crucial role of
technology in healthcare.
Enhanced Radiology Workflows
Advancements in technology have revolutionized radiology workflows, making the process more efficient and accurate. Digital imaging technologies, such as
PACS (Picture Archiving and Communication Systems) and RIS (Radiology Information Systems), allow for the seamless storage, retrieval, and sharing of medical
images. The specialists AbbaDox say that this reduces the time needed to diagnose and treat patients, significantly improving the overall efficiency of radiology
departments. Additionally, AI-powered tools can assist radiologists by highlighting potential areas of concern within images, ensuring that abnormalities are not
overlooked. These improvements contribute to faster, more accurate diagnoses and better patient outcomes.
The Self-Care Strategy Group (SCSG) has written to Health Secretary, Wes Streeting, urging the new Labour government to fully realize self-care's benefits.
With PAGB serving as the secretariat for the Group, signatories of the letter also include CPE, RPS, CCA, NPA, the Dispensing Doctors' Association, the National
Association of Primary Care, the Patient Information Forum, and the Self Care Forum.
The nine members highlight the importance of collaborative efforts to build an NHS fit for the future.
In the letter, the group emphasises the potential of self-care to alleviate pressure on primary and emergency healthcare services.
They call for expanded prescribing rights, optimised digital health tools, and streamlined referral processes between primary, diagnostic, and specialist care
services.
A new bill was introduced to Parliament on Wednesday (20 March) to prohibit the sale of tobacco to children under the age of 15, delivering on the
Prime Minister's commitment to create a smokefree generation.
The Tobacco and Vapes Bill aims to protect future generations from the harmful impacts of smoking, thereby saving thousands of lives and billions of pounds
for the NHS.
The bill will also introduce new powers to restrict vape flavours and packaging deliberately targeted towards children, as well as allow the government to
change how they are displayed in shops, moving them out of sight of children and away from products that appeal to them, like sweets.
Additionally, enforcement officers' powers will be strengthened with 'on the spot fines' of £100 to ensure compliance with the new laws. This complements
the existing maximum fine of £2,500 that local authorities can already impose. It will also become illegal to provide free samples of vapes to children under
the age of 18.
The number of people living to be 100 or more increased by 3.7 per cent in England and Wales in 2022, compared to the previous year, according to new
figures from the Office for National Statistics (ONS).
ONS data also revealed that the number of centenarians in the UK has more than doubled in the last two decades.
Wales has more centenarians (27 people per 100,000 aged 100 or over) than England (25 people per 100,000).
It's good news that more people are living into their second century, but it also means that we may need to rethink our health plans for a longer future, a leading
testing expert has suggested.
The Royal Pharmaceutical Society (RPS) has said that it strongly supports the UK government's proposal that individuals born on or after 1 January 2009
should be prohibited from legally purchasing tobacco products.
It has also shown its agreement to several other actions proposed by the Department of Health and Social Care's (DHSC) for 'Creating a Smokefree Generation and
Tackling Youth Vaping' including:
The inclusion of all tobacco products, cigarette papers, and herbal smoking products in the new legislation.
Restrictions on the sale and supply of disposable vapes, and vape flavours.
RPS President, Professor Claire Anderson, said: "Our recommendations reflect a commitment to creating a future free from the harms of tobacco and youth vaping.
It's crucial to prohibit access for the youngest generation, regulate all tobacco-related items, and address the allure of flavoured e-cigarettes."
The Department of Health and Social Care (DHSC) has announced 30 pence increase in prescription charges from £9.35 to £9.65 for each medicine or appliance
dispensed.
Board Chair for England at RPS, Thorrun Govind commented: "This is a kick in the teeth for people in England who are already struggling with rising bills and food
prices.
"Patients groups have warned that people are not collecting prescription medicines due to cost and pharmacists are seeing this worrying trend first-hand.
"A Government impact assessment noted the risk of adverse effects of people not taking their medicines, resulting in future health problems for the individual,
potential hospital admissions, and a subsequent cost to the NHS.
"This decision seems to prioritise revenue generation over ill-health prevention and undermines the principle of an NHS free at the point of use.
The UK government will lay legislation today (13 December 2023) to allow the General Medical Council (GMC) to begin the process of regulating medical
associates to expand their roles in the NHS.
This will support plans to reduce pressure on doctors and GPs and improve access for patients, the Department of Health and Social Care (DHSC) said.
Physician associates (PAs) and anaesthesia associates (AAs) will have the same levels of regulatory oversight and accountability as doctors and other regulated
healthcare professionals once the regulations come into force, which is expected at the end of 2024.
The GMC will design and deliver detailed regulatory processes for registration, education, standards and fitness to practise for both professions.
In response to stakeholder feedback, the General Pharmaceutical Council (GPhC) is developing a streamlined, single route to registration that will replace
the current multiple-pathway system for overseas pharmacists wishing to practice in Great Britain.
This revised approach will include updated standards for the education and training of internationally qualified pharmacists, with all applicants still required
to pass a registration assessment.
The GPhC's Council intends to streamline the registration pathway, reducing the two-year process to one-year process.
This new pathway will encompass both university study and in-practice training.
Historically, pharmacists qualified within the European Economic Area (EEA) or European Free Trade Association (EFTA) have been eligible for qualification
recognition in Great Britain.
While this recognition has been extended until September 2028, the future requirement for EEA-qualified pharmacists to undergo the new registration route
remains contingent on forthcoming government decisions.
Initially, the GPhC had explored the development of three distinct registration routes for internationally-qualified pharmacists, "however decided to change
this proposed approach after considering feedback from stakeholders."
A £5m project has been launched to introduce new blood tests in the National Health Service (NHS) that can diagnose Alzheimer's disease.
The blood tests could be available on the NHS within five years and they can diagnose the disease earlier and more accurately than current methods, experts have said.
Alzheimer's Research UK, the Alzheimer's Society and the National Institute of Health and Care Research have jointly launched the project.
Susan Kohlhaas, Executive Director of Research and Partnerships at Alzheimer's Research UK, said that the NHS doesn't possess the "required levels of diagnostic
infrastructure" to cope with the "growing demand" for dementia diagnosis.
"Low-cost tools like blood tests that are non-invasive and simpler to administer than current gold standard methods are the answer to this," she added.
The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin.
It's final draft guidance is expected to be available on the July 20.
Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with
controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides.
NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo.
Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.
A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients.
The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and
weight-related health issues.
The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings.
The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity
simultaneously.
Although it is not authorised to use on the NHS as yet but future approvals can be predicted.